Therapeutics with conformationally restricted monomers
View Patent ↗This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).
1. An oligomer comprising one or more nucleotide monomers and one or more conformationally restricted Monomers R having the formula
wherein X is independently selected for each occurrence from O, S, CH 2 , C═O, C═S, C═CH 2 , CHF and CF 2 ;
R 2 and R 3 are linkages of the monomer to flanking monomers in the oligomer; and
B is a nucleobase or nucleobase analog;
wherein the oligomer has a 5′ end and a 3′ end, a center position, and a length of from 10 to 40 monomers;
wherein the oligomer comprises a sequence for PLK1 selected from SEQ ID NOs:161-170;
wherein the oligomer comprises a Monomer R in one or more of the four positions flanking the center position of the oligomer;
wherein each nucleobase or nucleobase analog of the oligomer is independently selected from adenine, cytosine, guanine, uracil, hypoxanthine, thymine, 7-deazaadenine, inosine, C-phenyl, C-naphthyl, inosine, an azole carboxamide, nebularine, a nitropyrrole, a nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-methyluridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O 6 -methylguanine, N 6 -methyladenine, O 4 -methylthymine, 5,6-dihydrothymine, 2-thioribothymidine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine, deoxyuridine, and deoxy analogs of any of the foregoing.
2. The oligomer of claim 1 , wherein the nucleotide monomers are ribonucleotide monomers.
3. The oligomer of claim 1 , wherein the nucleotide monomers are deoxyribonucleotide monomers and ribonucleotide monomers.
4. The oligomer of claim 1 , wherein the oligomer acts as an antisense, microRNA or antagomir.
5. A duplex oligomer comprising a first strand and a second strand, each strand comprising from 10 to 40 monomers, wherein each strand comprises one or more nucleotide monomers and one or more conformationally restricted Monomers R having the formula
wherein X is independently selected for each occurrence from O, S, CH 2 , C═O, C═S, C═CH 2 , CHF and CF 2 ;
R 2 and R 3 are linkages of the monomer to flanking monomers in the oligomer; and
B is a nucleobase or nucleobase analog;
wherein the oligomer has a 5′ end and a 3′ end, and a center position;
wherein the duplex oligomer comprises a sequence for PLK1 selected from SEQ ID NOs:161-170;
wherein the duplex oligomer comprises a Monomer R in one or more of the four positions flanking the center position of the duplex oligomer, in either the first strand or the second strand;
wherein each nucleobase or nucleobase analog of the oligomer is independently selected from adenine, cytosine, guanine, uracil, hypoxanthine, thymine, 7-deazaadenine, inosine, C-phenyl, C-naphthyl, inosine, an azole carboxamide, nebularine, a nitropyrrole, a nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-methyluridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O 6 -methylguanine, N 6 -methyladenine, O 4 -methylthymine, 5,6-dihydrothymine, 2-thioribothymidine, 5,6-dihydrouracil, 4-methylindole, ethenoadenine, deoxyuridine, and deoxy analogs of any of the foregoing; and
wherein the first strand and the second strand form a single double-stranded region of the duplex oligomer.
6. The duplex oligomer of claim 5 , wherein the nucleotide monomers are ribonucleotide monomers.
7. The duplex oligomer of claim 5 , wherein the nucleotide monomers are deoxyribonucleotide monomers and ribonucleotide monomers.
8. The duplex oligomer of claim 5 , wherein the duplex oligomer has a blunt end.
9. The duplex oligomer of claim 5 , wherein the duplex oligomer has a 3′-end overhang.
10. A method for decreasing expression of a target mRNA in a cell or an organism comprising administering to the cell or organism the duplex oligomer of claim 5 .